

## Index

### a

activated protein C 7, 11  
 – schematic diagram 7  
 adaptor molecules 80  
 alien tissue 80  
 – CHO 80  
 – NS0 80  
 – Sp2/0 cells 80  
 AMG114 molecule 307  
 – carbohydrates on 307  
 – clinical testing in CIA patients 307  
 – glycoengineering 307  
 $\alpha$ -amidated peptide 253, 254, 256, 257, 260, 265, 266, 269–271  
 – dual recombinant expression process 266  
 – recombinant production 265  
 – species distribution of 257  
 $\alpha$ -amidated peptide hormones 254, 270  
 – conversion of prohormones into mature 254  
 – disease indications 271  
 $\alpha$ -amidating enzyme ( $\alpha$ -AE) 12  
 $\alpha$ -amidation 260, 262  
 – C-terminus 269  
 – *in vitro* 261  
 – influence of pH 262  
 – reactive oxygen species (ROS) 260  
 – standard reaction components 261  
 amino acid side chains 87, 258  
 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS) 35  
 amplifiable gene 52  
 – dihydrofolate reductase (DHFR) 52  
 – glutamine synthetase (GS) 52  
 animal cell cultures 51  
 antibody(ies) 9, 34–36, 65, 68, 79, 80, 86, 91, 92, 94–100, 123, 156, 157, 159, 172, 227, 277, 351

– anti-CD20 monoclonal antibody 159  
 – anti-CD28 antibody 99  
 – anti-CD33 antibody 98  
 – anti-D antibodies 93  
 – based products 9  
 – basic structure/function 80–83  
 – fragments 99  
 – glycoforms 100  
 – immunoglobulin isotypes 84  
 – TGN 1412 99  
 – therapeutics 79  
 antibody-dependent cellular cytotoxicity (ADCC) 57, 68, 89, 157  
 – activity 94, 95  
 anti-parallel  $\beta$ -sheets 81  
 ascorbic acid 233  
 Ashkenazi Jewish population 320  
 asialoglycoprotein receptor (ASGR) 309  
 asialylglycoprotein receptor (ASGPR) 91, 92  
*Aspergillus niger* 261

### b

baby hamster kidney (BHK) cells 60, 61, 65, 299  
 bacterial glycoproteins 205  
 – bacterial polysaccharides 205  
 bacterial glycosylation technologies 193–195, 197  
 – advantage 197  
 – characteristics 203  
 – crystal structures 197  
 – 3D design 197  
 – eukaryotes 197  
 – protein glycosylation 194  
 bacterial polysaccharide metabolizing enzymes 193  
 bacterial systems 149  
 baculovirus 174, 178, 322

- expressed proteins 322
  - *ie* promoter(s) 174, 178
  - baculovirus encoded
    - glycosyltransferases 175
  - *N*-acetylglucosaminyltransferase I 175
  - *N*-acetylglucosaminyltransferase II 176
  - galactosyltransferase 175
  - sialyltransferase 175
  - *trans*-sialidase (TS) 176
  - baculoviruses encoded sugar processing
    - genes 176
    - *N*-acetylmannosamine kinase 176
    - CMP-sialic acid synthetase 177
    - sialic acid synthetase 177
    - UDP-GlcNAc 2-epimerase 176
  - baculovirus expression vector system (BEVS) 165, 166
    - core  $\alpha$ 1,3 fucosyltransferase 172
    - derived *N*-glycoprotein product 166, 170
    - encoded firefly luciferase gene 184
    - lack of mannose-6-phosphate 172
    - *N*-glycan processing enzymes 171
    - processing  $\beta$ -*N*-acetylglucosaminidase 171
    - produced recombinant *N*-glycoproteins 170
  - baculovirus expression vector system
    - N*-glycosylation 174
  - baculovirus encoded glycosyltransferases 175
  - baculoviruses encoded sugar processing
    - genes 176
  - baculoviruses use 174
  - promoter choice 174
  - baculovirus expression vector system product
    - pipeline 166
    - Chimigen vaccines 167
    - FluBlok 167
    - influenza virus-like particles 167
    - Provenge 167
    - recombinant *N*-glycoproteins 166
    - Specifid™ 168
  - $\beta$ -barrel structure 81
  - batch culture 61, 62
    - $\gamma$ -interferon production 62
  - beta-elimination process 37
  - binary expression system 165
  - bioconjugate production 204
    - *Escherichia coli* 204
  - biologically active proteins 149
  - biological molecules 34
    - nucleic acids 34
    - proteins 34
  - biopharmaceuticals 2, 7, 9, 57, 165
    - glycosylated 9
    - IgG proteins 57
    - insect cell glycosylation patterns 165
    - products profiles 2
    - products sub-categories 2
    - PTMs 7
    - PEGylated 13
    - blood factor(s) 2, 9, 11, 12
      - Asp64 233
      - blood clotting 221
      - factor IX (FIX) 2, 221
      - factor VII (FVII) 2, 221
      - factor VIII 2
      - $\beta$ -hydroxylation of Asp64 221
      - in liver 221
      - treatment of hemophilia B 221
    - blood clotting mechanisms 18
    - Bombyx mori* larvae 169
    - bovine pancreatic trypsin inhibitor (BPTI) 283
    - bovine prothrombin 215
      - $\text{Ca}^{2+}$ -loaded Gla domain 215
    - building enzymes 22
      - glycosyltransferases 22
    - Burkitt's lymphoma 98
- c**
- Campylobacter jejuni* 194, 195
  - Candida albicans* 152
  - capillary affinity electrophoresis (CAE) 39
  - capillary electrophoresis (CE) 39
    - oligosaccharides mapping 39
    - oligosaccharides separation 39
  - carbohydrate addition 300
    - AMG114 307–308
    - darbepoetin alfa 303–307
    - effect 309
    - glycoengineered ESAs 308–309
    - glycoforms 302–303
    - mechanism of clearance 309–311
    - O-linked 301
    - rules 300–302
    - threonine 301
  - carbohydrate remodeling process 326
    - effect 325
  - $\gamma$ -carboxy glutamate (Gla) 211
    - biosynthesis of 217
    - blood clotting protein 212
    - catalytic (serine protease) domain 213
    - Cys residues 214
    - epidermal growth factor-like domain (EGF1) 213
    - $\gamma$ -carboxylated vertebrate proteins 214
    - NMR structures 216
    - *N*-terminus of mature polypeptides 212

- protein-protein interactions 215
- vitamin K-dependent polypeptides 217
- vitamin K redox cycle 218
- X-ray crystallography 216
- $\gamma$ -carboxylated biopharmaceuticals 219
  - factor IX (FIX) 219
  - factor VII (FVII) 221
  - protein C/activated protein C 222
  - prothrombin 223
- $\gamma$ -carboxylated proteins 212, 226
  - analytical characterization of 227–228
  - cone snails 213
  - enzyme assays 228
  - metal binding-induced structural changes 228
  - metal content 227
  - methods for detecting Gla 227
  - phospholipid membrane binding assays 228
  - purification 226
  - roles in 212
- $\gamma$ -carboxylation process 211
  - biological function of 211–214
  - biopharmaceuticals 219–224
  - biosynthesis of Gla 217–219
  - cellular carboxylation capacity 224–226
  - conotoxins 224
  - Gla domain 214–217
  - Glu residues 215, 219
  - in  $\text{Ca}^{2+}$  binding 212
  - of glutamyl (Glu) 211
  - recognition site 217
- carboxyl-terminal segment 110
- catabolic pathway 319
- catalytic cysteine residues 282
  - DsbC 282
- cDNA, sequence 111, 327, 328
- cell culture process 327
- cell signaling system 56
- cell surface membrane 109
- cell surface receptor(s) 172, 324
- cellular carboxylation capacity 224
  - $\gamma$ -carboxylation machinery 225
  - enhancement of 224
  - inhibition of calumenin expression 226
  - propeptide/propeptidase engineering 226
- cellular glutamine metabolism 65
- cellular mannose receptor (MR) 94
- cellular splicing mechanisms 183
- Chaperone molecules 25
  - calnexin 25
  - calreticulin 25
- charge distribution profile 129
- chimeric proteins 167
- Chimigen technology 167
- Chinese hamster ovary (CHO) cells 51–53, 56, 59–61, 63, 66, 68, 80, 94, 119, 130, 221, 327, 331
  - cell culture 59
  - cell-derived gonadotropins 130
  - cell line(s) 80, 95
  - cell proteins 327
  - complex type N-linked glycans 130
  - core-fucosylation 52
  - glycosylation metabolism 56
  - glycosylation pathways 52
  - mutagenesis 52
  - mutants 52
  - O-glycan synthesis 53
  - O-linked glycans 53
  - recombinant bifunctional rPAM 268
- choriogonadotropin (CG) hormones 109
  - clearance 122
  - deglycosylation 123
  - induced fluorescence resonance energy 123
  - $\beta$ -subunit genes 111, 121
- chromatographic fractionation techniques 343
- clonal cells lines 178
- clone selection process 99
- CMP-sialic acid 175, 179, 182
  - synthetase enzyme 177
- complement dependent cytotoxicity (CDC) 89
- complex cell-type *in vitro* assay systems 124
- complex glycan structures 19
  - formation 19
  - $\alpha/\beta$  glycosidic bonds 19
- computer-assisted algorithms 36
- congenital disorders of glycosylation (CDG) 79
- conotoxins 234
  - biopharmaceutical potential 234
- Conus marmoreus* 234
- copper sulfate titration 262
- core-fucosylation pathway 57
- correlated spectroscopy (COSY) 40
- cost of goods (CoG) 79
- cost of treatment (CoT) 79
- Crohn's disease 18
- cystine knot proteins 112, 113
  - crystal structures 113
- cytoplasmic proteins 265, 287
  - gene coding 287
  - glutaredoxin systems 287
  - thioredoxin systems 287

**d**

d-arabinofuranose (d-Araf) 201  
 – alpha-1,5-linked 201  
 darbepoetin, *see* human erythropoietin (EPO)  
*Desulfovibrio desulfuricans* 194  
 dextran ladder, *see* glucose polymers  
 2D gel electrophoresis 66  
 2,6-diaminopyridine (DAP) 35  
 differential scanning micro-calorimetry (DSC) 87  
 dimeric protein 284  
 direct expression technology 269  
 – expression levels of peptides 269  
 – fermentation protocol 269  
 dissolved oxygen (DO) 66  
 disulfide bond (Dsb) 278, 286  
 – oxidation-reduction cycles 279, 280, 284  
 – pathway 286  
 – dimeric protein 284  
 disulfide bond formation 10, 278, 286  
 – catalyzed process 278  
 – cytoplasm 286  
 – disulfide isomerization pathway 282  
 – DsbA/DsbB oxidizing protein 279, 280  
 – *E. coli* thioredoxin mutants 281  
 – ER oxidoreductin 289  
 – Ero1 regulatory role 290  
 – in bacterial periplasm 278  
 – in endoplasmic reticulum 288  
 – new oxidation pathway 281  
 – PDI functions 288  
 – revised model for formation 286  
 – role 10  
 – thiol group 278  
 disulfide isomerization pathway 282  
 – periplasmic protein disulfide isomerase 282  
 dolichol oligosaccharide precursor 24  
 – building 24  
 – positioning 24  
 dopamine-beta-monooxygenase (DβM) 256  
 double-stranded RNA (dsRNA) 183  
 – encoding construct 184  
*Drosophila melanogaster* 173  
 – FDL protein 171  
 DsbC *see* dimeric protein  
 D409V Gaucher mouse model 331

**e**

Edman degradation 235  
 effector activities 91–96  
 effector function profile 99

electron transport chain 280  
 – Cys41/Cys44 280  
 – DsbB 280  
 electrospray ionization (ESI) 41  
 endocrine-governed mechanism 127  
 endoplasmic reticulum (ER) 113, 150, 288, 289  
 – disulfide bond formation 289  
 enzymatic α-amidation 259, 263  
 – kinetic parameters 259  
 – temperature influence 263  
 enzyme replacement therapy (ERT) 319, 322, 323, 330  
 – Ceredase 319  
 – Cerezyme 319  
 – clinical studies 323  
 – glycoengineering 324  
 – mannose receptor identification 324, 330  
 – placental glucocerebrosidase use 323–327  
 – role in macrophage uptake 324  
 epidermal growth factor (EGF) 229, 346  
 – Ca<sup>2+</sup>-binding 229  
 – contain Hya/Hyn 231  
 – FIX/FX 230  
 – functional importance 231  
 – β-hydroxylation of 231  
 – schematic of the Ca<sup>2+</sup>-binding site 230  
 erythro-β-hydroxyasparagine (Hyn) 211, 232  
 – biosynthesis 232  
 erythro-β-Hydroxyaspartic acid (Hya) 211, 232  
 – Asp/Asn residue 232  
 – biosynthesis 232  
 erythropoiesis stimulating agent (ESA) 306, 309  
 – clearance 309  
 erythropoietin (EPO) 67, 159, 299, 352  
 – endogenous 299  
 – heterogeneity analysis 66  
 – receptor-mediated metabolism 310  
 – role 310  
*Escherichia coli* 7, 12, 99, 149, 160, 178, 193, 264, 283, 286, 288  
 – disulfide bonds 286  
 – β-galactosidase 178  
 – glycosylated protein 7  
 – isomerization pathway 283  
 – periplasm 283, 286  
 eukaryotic protein processing 166  
 eukaryotic recombinant proteins 283  
 eukaryotic systems 149, 165, 196  
 European Union (EU) 3  
 – approved biopharmaceutical products 3–5  
 eye-specific marker 181

**f**

- Fabry's disease 320
- galactosidase A deficiency 320
- fast atom bombardment (FAB) 41
- Fcg receptors (FcgR) 88
- IIIa receptor 159
- human receptor 86
- fed-batch culture 63, 64
- nutrient consumption 64
- product accumulation 64
- strategies for culture studies 63
- fibroblast growth factor-1 (FGF-1) 156
- fluorescence-assisted cell sorting (FACS) 332
- fluorophore-assisted carbohydrate electrophoresis (FACE) 39, 329
- oligosaccharides mapping 39
- oligosaccharides separation 39
- follicle-stimulating hormone (FSH) 67, 109, 110, 121, 129, 131
- $\alpha$ -subunit 118
- analogs 132
- binding site 113
- chromatofocusing separation 125
- glycan structure 126
- glycoforms 124, 128
- hormone glycosylation 121
- *in vitro* B/I ratio 129
- isoforms 122
- mediated signal transduction 123
- oligosaccharides 129
- plasma disappearance curves 125
- production 128
- receptor 123
- recombinant human 125
- single-chain 124
- structure 124
- wild type 120
- fragment antigen binding (IgG-Fab) regions 82, 92, 96–98
- glycoforms 92
- glycosylation 96–98
- region 96
- fragment crystallizable activities 94
- bisecting *N*-acetylglucosamine Influence 94
- fucose influence 94
- fragment crystallizable effector functions 88, 93
- inflammatory cascades 88–90
- fragment crystallizable (IgG-Fc) regions 82, 84, 87, 89–99
- binding proteins 89, 95
- definition 82
- diantennary oligosaccharide structures 83

- drug-fusion proteins 91
- fragment 86
- galactosylation 84, 92
- glycoform profile 84, 87, 91–96, 98
- normal human 83, 85, 93
- oligosaccharides HPLC profile 84, 85, 97, 98
- oligosaccharides sialylation 92
- receptor(s) 82, 89, 90, 99
- regions 82
- structure 92, 93
- $\alpha$ 1,6 fucosyltransferase ( $\alpha$ 1,6FT) 57
- nascent glycoprotein 57
- functional glycomics 67–68
- fungal protein expression systems 159

**g**

- galactose-fed cultures 63
- $\beta$ -galactosidase 324
- galactosylated anti-D antibody 93
- galactosylation pathway 65
- galactose feeding 65
- gas-liquid chromatography (GLC) 37, 41
- monosaccharides Linkage Position Determination 41
- Gaucher's disease 13, 172, 319–322, 325, 334
- ERT development 325
- GDP-mannose 4–6 dehydratase (GDM) 57
- gene encoding 225
- cloning of 225
- genetic engineering 2
- genetic methods 155
- genome sequencing 132
- globotriaosylceramide (GL-3) 320
- glucocerebrosidase (GCase) 320–322, 324–326, 328–331, 333, 334
- carbohydrate chains remodeling 325
- carbohydrate-remodeled 331
- carrot cell-expressed 334
- mannose receptor binding 331
- monosaccharide compositions 329
- purification process 326
- X-ray crystal structure 321
- glucose polymers 38
- glucose units (GU) 38
- glutamine fructose 6-phosphate amidotransferase (GFAT) 64
- $\gamma$ -glutamyl carboxylase 217
- polypeptide substrate 217
- propeptide mediates binding 217
- glutamyl residue (Glu) 211
- post-translational conversion 211
- glutathione reductase (*gor*) 286
- glycan 18, 20, 39, 41, 121

- chains termination 19, 33
- fluorescently-labeled 39
- glycozymes synthesis 22
- mass-to-charge ratio (m/z) 41
- monosaccharides units 18–20
- role 121
- glycan detection 34
  - lectin binding 34
  - periodic acid-schiff (PAS) reaction 34
  - pulsed amperometric detection (PAD) 35
- glycan-directed enzyme replacement therapy 319–323
  - Gaucher's disease 320–321
  - glucocerebrosidase 321–322
  - lysosomal storage diseases 319
- glycan heterogeneity 55
  - N-acetyl glucosaminyltransferases 55–57
  - fucosylation 57
  - sialylation 58–60
- glycan labeling 35
  - fluorescent labels 35
  - radiolabels 35
- glycan motifs 32, 33
  - ABO blood group antigens 33
  - Cad/Sd blood group antigens 33
  - Lewis blood group antigens 33
- glycan profiling 35
  - microarrays use 35
- glycan structures 17, 23, 51, 68, 124
- glycine-extended fatty acids 254
  - *in vitro*  $\alpha$ -amidation 253
- glycine-extended peptides 260, 266
  - $\alpha$ -amidation 260–263
  - direct expression process 266
  - $\alpha$ -hydroxylation 260
  - *in vitro*  $\alpha$ -amidation 260
  - precursors 266
  - purification 266
  - upstream signal sequence 266
- glyco-catch approach 35
- glycoconjugate vaccines 204
- glycoengineered erythropoiesis stimulating agent 308
  - AMG114 308
  - darbepoetin alfa 308
  - rHuEpo 309
- glycoengineered glucocerebrosidase 330
  - alternative expression systems use 333
  - mannosidase inhibitors use 330
  - mutant cell lines use 333
  - targeting mannose receptor strategies 330
- glycoengineered rHuEpo glycosylation analogs 306
- glycoengineering 319, 324
  - cerezyme case study 319
  - strategies 319
  - targeting strategy 324
- glycoform profile 97
- glycome exploring 36
  - one/two-dimensional gel electrophoresis 36
- glycoprotein 17, 177, 178, 204
  - chemical release 36
  - containing humanized glycans 204
  - glycans structural complexity 19
  - glycoprotein of interest (GOI) 174
  - polypeptide sequences 17
  - production 51
  - synthesis 204
- glycoprotein hormone 111–115, 117, 121, 125, 129, 132
  - glycosylation 115, 132
  - *in vitro/in vivo* bioactivity 125
  - physicochemical properties 121
  - processing 132
  - producing tissues 113
  - receptors 109
  - role 114
  - structurally-related 129
  - sulfation 115
- glycoproteins separation method 36
  - HPLC 36
  - mass spectroscopy 36
  - SDS-PAGE 36
- glycosidic linkage formation 21
- glycosylation process 2, 8, 51, 54, 56, 58, 84, 86, 87
  - case study 51
  - central reaction network 56
  - growth effect 54
  - impact on stability 87
  - impact on structure 86
  - importance 109
  - normal human IgG 84–86
  - pathway 59
  - profiles 80
  - protein production rate effect 54
- glycosylation culture parameters 61–67
  - ammonia 65
  - fed-batch cultures 63
  - galactose supplement 65
  - glucosamine supplement 64
  - nutrient depletion 61
  - oxygen 66
  - pH 66
- glycosyltransferase 22, 23, 52, 173
  - N-acetylglucosaminyltransferases II-IV 173

- families 22
- galactosyl/sialyltransferase 173
- glycosyltransferase donor substrates 174
- lack of 173
- reactions 52
- transglycosylation reactions 23
- Golgi apparatus (GA) 22–25, 86, 150, 154, 159
- factors 23
- N-glycosylation Step 24
- N-linked oligosaccharides processing 25
- role 23
- secretory pathway 23, 24
- gonadotropin 109, 118, 121–122, 124, 126, 130, 131
- binding 123
- degree of charge heterogeneity 118
- function 121, 124, 126
- glycoforms 126
- glycosylation 114–121
- *in vivo* biological potency 122
- metabolic clearance rate 122
- microheterogeneity 132
- role in folding 121
- role in secretion 121
- role in subunit assembly 121
- signal transduction 123
- structure 111–114
- therapeutic applications 130–132
- gonadotropin glycosylation regulation 127
- androgens effects 128
- estrogens effects 127
- gonadotropin-releasing hormone effects 129
- gonadotropin-releasing hormone (GnRH) 128, 129
- role 129
- triggered alterations 130
- G protein-coupled receptors 109
- heterotrimeric 111
- granulocyte colony-stimulating factor (G-CSF) 349
- growth hormone-insulin growth factor 1 (GH-IGF-1) 351

## **h**

- Haemophilus influenza* 205
- Halobacterium salinarium* 194
- healthcare biotechnology 1
- $\alpha$ -helical transmembrane domains 110
- hepatocyte receptors 122
- heterologous proteins 288
- in *E. coli* 288
- high-performance anion exchange chromatography (HPAEC) 39
- high-performance liquid chromatography (HPLC) 37, 38
- normal phase HPLC (NP-HPLC) 38
- oligosaccharide mapping 38
- oligosaccharide separation 38
- weak anion exchange high-performance liquid chromatography (WAX-HPLC) 38
- high pH anion exchange chromatography, *see* High-performance anion exchange chromatography (HPAEC)
- homology modeling 110
- human FSHR 110
- horseradish peroxidase (HRP) 172
- epitope 172, 184
- human B cell lymphoproliferative disease 98
- human cells 18
- glycosylation building blocks 18–19
- line(s) 57, 99, 150
- human embryonic kidney (HEK293) cells 223
- human erythropoietin (EPO) 13, 60, 68
- Aranesp 13
- human FSH (hFSH) glycoform glycosylation 116
- receptor 124
- human glycoprotein hormone 114
- glycosylation sites 114
- human granulocyte-macrophage colony-stimulating factor 167
- human growth hormone (hGH) 349
- human immunoglobulin 90
- catabolism 90
- glycoform profile 100
- myeloma IgG proteins 92, 97
- pharmacokinetics 90
- placental transport 90
- human placental free- $\alpha$  lacks O-glycans 114
- human tissue plasminogen activator (t-PA) 54, 178
- hydrophobic interaction chromatography (HIC) 267
- $\beta$ -hydroxylase enzyme assays 235
- hydroxylated amino acids 231
- biosynthesis 231, 232
- hydroxylated biopharmaceuticals 233
- conotoxins 234
- factor IX (FIX) 233
- protein C/activated protein C 233
- $\beta$ -hydroxylated proteins 235
- analytical characterization 235
- $\beta$ -hydroxylase enzyme assays 235
- hypogonadotropic hypogonadism 130
- hypothalamic-releasing factors 132

**i**

- immune response 82
- immunogenic proteins 326
- immunoglobulin (Ig) 67, 81
  - alpha carbon backbone structure 83
  - classes 67, 81, 84
  - dissolved oxygen Effect 67
  - Fc region 88
  - four-chain structure 81
  - heavy chains 82
  - IgG antibody 68, 81, 84, 95, 99
  - IgG glycoform profile 67
  - IgG heavy chain 88
  - IgG molecule(s) 81–83, 86, 88, 96
  - IgG protein(s) 84, 168
  - IgG-like domain(s) 321, 322
  - light chains 82
- in vitro* fertilization protocols 112
- in vitro* models 126
- influenza virus-like particles 167
- insect cell(s) 166, 175, 182
  - N-glycosylation patterns 166
  - derived glycoproteins 168
  - lines 170
  - mammalian epimerase/kinase enzyme 182
  - lepidopteran cell(s) 165, 182, 183
  - lines 172
  - N-glycosylation pathway 182
- insect glycoprotein N-glycan structure 168
  - hybrid/complex N-glycans 170
  - sialylated N-glycans 170
- intact oligosaccharides 37
  - chemical release 37
  - enzymatic release 37
- $\gamma$ -interferon (IFN $\gamma$ ) 60, 61, 169
  - recombinant 169
- interleukin-2 351
  - immunoregulatory lymphokine 351

**j**

- JAR choriocarcinoma cells 126

**k**

- 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) 177
- Kitasatosporia kifunense* 68
- Kluyveromyces lactis* 152
- Kupffer cells 122, 320, 323, 324

**l**

- lipid-linked oligosaccharides (LLOs) 196
  - PglB 197
- Lipinski's rules 269

- lipoarabinomannan (LAM) polymers 201
- luteinizing hormone (LH) 109, 111
  - CG $\beta$ -subunit genes 111
  - glycan structure 126
  - glycoforms 124
  - glycosylation 130
  - isoforms 128
- luteinizing hormone and CG bind to same receptor (LHCGR), 111
  - green fluorescent protein 123
  - yellow fluorescent protein chimeras 123
- Lymantria dispar* cells 169
- lysosomal membrane glycoprotein-2 (LAMP-2) 54, 322
  - deficient cells 322
  - polyglucosamine formation 54
- lysosomal storage diseases (LSDs) 319, 322
  - glycan-directed enzyme replacement therapy 319–323
  - serum acid phosphatase activity 326

**m**

- mammalian cell 159
  - case study 51
  - Chinese hamster ovary (CHO) 154
  - glucocerebrosidase 333
  - glycosyltransferases 177
  - human embryonic kidney (HEK) 293 154
  - lines 51, 154
  - O-linked glycosylation 153
- mannan binding lectin (MBL) 89, 331
- mannose 6-phosphate (M6P) 322, 332
  - modification 172
- mannose 6-phosphate receptor (MPR) 89, 323, 330–332
  - cation-dependent 323
  - cation-independent 323
  - macrophage 332
  - pathway 323
- mannose binding protein 171, 331
- $\alpha$ -mannosidase II (MNSII) 157
- mass spectrometry (MS) 40
  - analysis 37, 86
  - ionization 41
  - oligosaccharide mass determination 40
- matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) 41
- matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) 119
- megakaryocyte growth and development factor (MGDF) 349
- membrane-associated lysosomal protein 326

- membrane bound *N*-glycoprotein precursors 167
  - monoclonal antibody 156, 157
    - anti-collagen type II antibodies 94
    - 9G8a binds 304
    - technology 2
  - monosaccharides analysis 36
    - monosaccharide linkage data 37
    - monosaccharide sequence 37
    - sequential exoglycosidase digestions 37
  - mucin-type O-linked glycoprotein glycosylation 28–29
    - no consensus sequence 29
  - muscle eye-brain disease (MEB) 154
  - mycobacteria cell walls 201
- n**
- N*-acetylglucosamine (GlcNAc) 56, 330
    - $\beta$ -*N*-acetylglucosaminidase 171
    - residues 115
    - sulfate terminal sequence 117
    - transferase 115, 116, 117, 118, 127
  - N*-acetyl glucosaminyltransferase (GnT) enzymes 55, 157, 173, 174, 333
    - core 2 GlcNAc transferase (C2GnT) 53
    - $\beta$ -1,2 GNT I activity 156
    - GnT-I activity 173, 175, 333
    - GnT-III gene 94
    - transferrase I 333
    - transferase II 157
  - N*-acetylmannosamine (ManNAc) 59
  - N*-acetyl-neuraminic acid (NANA) 60
    - CMP transport 59
  - N*-glycan processing 174
    - functions 174
    - genes 174
    - machinery 174
  - N*-glycolyl-neuraminic acid (NGNA) 60, 98
  - N*-glycosylation pathway 28, 56, 96, 150, 152, 154, 170, 179, 183
    - hybrid/complex *N*-glycans 170
    - in fungi 150
    - profile 156
    - reaction network 56
    - reducing deleterious activities 183
    - structure 150
  - N*-glycosylation system 194
    - acceptor protein 195–197
    - bioconjugate vaccines 204–205
    - *C. jejuni* 194
    - characteristics of 203
    - conformational requirements for 196
    - eukaryotic system 196
    - functions 94
    - glycoengineering 205–206
    - introduction 194–195
    - lipid-linked oligosaccharide (LLO) substrate 197
    - *N*-OTase 197, 198
    - PglB 197, 198
    - therapeutic (human) proteins 203–204
    - undecaprenol-pyrophosphate (Und-PP) lipid 199
  - N*-linked glycans 118–120, 124, 152
    - chains 150
  - N*-linked glycoproteins 24–27, 117, 150
    - biosynthetic pathway 117
    - classes 25
    - *N*-glycosylation step 24
    - pool 155
  - natural antibody response 100
  - negative ion nanospray mass spectrometry 41
  - Neisseria gonorrhoea* 201
  - non-fucosylated biantennary structures 120
  - non-Hodgkin's B-cell lymphomas 168
  - non-human glycans immunogenicity 61
  - non-mannose receptor proteins 334
    - MBL 334
  - novavax technology 167
  - NS0 cells 61, 65
  - nuclear magnetic resonance (NMR) 40
    - oligosaccharide analysis 40
    - study 93
  - nuclear overhauser effects (NOEs) 40
  - nuclear proteins 28
  - nucleic acid-based drugs 2
- o**
- O-glycosylation 152, 199
    - acceptor protein for 200
    - bioconjugate vaccines 204–205
    - characteristics of 203
    - glycoengineering 205–206
    - in fungi 152
    - in mammals 152
    - in neisseria 201–203
    - in *Pseudomonas aeruginosa* 200–201
    - *Neisseria meningitidis* 202
    - prokaryotic organisms 199
    - therapeutic (human) proteins 203–204
  - O-linked glycan(s) 31, 153
    - core structures 31
    - synthesis 32
    - regulation 32
  - O-linked glycoproteins 27–32
  - O-linked glycosylation 28
    - pathway 53

- types 28
  - O-linked mucin-type glycan core structures
    - synthesis 29
  - O/N-linked glycan chain extension 32
  - oligosaccharide structures 199
    - bacterial oligo/polysaccharide biosynthesis eukaryotes 199
    - transferred to proteins 199
  - oligosaccharyl transferase (OST) enzyme 25, 54
  - one enzyme-one linkage rule 22
  - optimal follicle maturation 131
- P**
- P. aeruginosa* 201
    - glycan structures in 201
    - O-glycosylation 201
  - Paget's disease 12
  - parathyroid hormone (PTH) 269
  - pauci-mannose structures 333
  - PEGylation protein 341, 350
    - covalent coupling of 341
    - importance of 341, 349
    - schematic drawing of 342
  - peptidyl- $\alpha$ -hydroxyglycine  $\alpha$ -amidating lyase (PAL) 253
  - peptidyl-proline *cis-trans* isomerases (PPIases) 277
    - ubiquitous proteins 277
  - peptidylamidoglycolate lyase (PGL) 256
  - peptidylglycine  $\alpha$ -amidating monooxygenase (PAM) 253
    - anion exchange (AEX) chromatography 267
    - assays for measurement of 254
    - bifunctional enzyme 256
    - bifunctional frog 264
    - Chinese hamster ovary (CHO) cells 267
    - cloning/expression of 263
    - co-expression of 265
    - genomic structure 257
    - glycine-extended peptide 256, 265
    - human bifunctional 264
    - mechanism of action 255
    - monooxygenase activity 254
    - optimization of 261
    - peptide  $\alpha$ -amidation reaction 255
    - purification of recombinant 267
    - recombinant 267, 268
    - species distribution of 257
    - structure-activity relationships (SAR) for rat 258–260
    - substrate specificity 253
    - tissue-specific forms of 258
  - peptidylglycine  $\alpha$ -hydroxylating monooxygenase (PHM) 253
    - bifunctional enzyme 256
    - frog skin 264
    - redox cycling 256
  - periodic acid-schiff (PAS) reaction 34
  - periplasmic protein disulfide 282
    - DsbC 282
  - piggyBac* system 181
  - pituitary biosynthetic mechanisms 127
  - pituitary glycoprotein hormones 120
  - placental enzyme 328
  - plant cell glycoproteins 334
  - plant/yeast expression systems 334
  - plasma cells 81
    - derived thrombin forms 223
    - glycoproteins 28, 168
    - non-proliferating 81
  - platelet-derived growth factor 112
  - poly(ethylene glycol) (PEG) 13, 348
    - activation towards amino/thiol residues 345, 346
    - general properties 343
    - granulocyte colony-stimulating factor 349
    - growth hormone releasing hormone (GHRH) 351
    - hemoglobin (Hb) 352
    - immunogenic proteins 348
    - interleukin-2 235
    - plasma kinetics 344
    - polymerization process 343
    - potential effects 347–348
    - practical importance 349
    - process 13
    - protein conjugates 342, 344, 347, 349, 350
    - ring-opening polymerization 343
  - polyacrylamide gel electrophoresis of fluorophore labeled saccharides (PAGEFS) 39
  - polyhedrin* promoter 174–177
  - polypeptide chain 27
    - N-glycosylation potential site 27
  - Pompe's disease 320
  - post-translational hydroxylation 229
    - biological function of 229
    - biosynthesis of hydroxylated amino acids 231–233
    - hydroxylated biopharmaceuticals 233–234
    - $\beta$ -hydroxylated proteins 235
    - partial amino acid sequences of 214
    - properties 220
    - schematic of the  $\text{Ca}^{2+}$ -binding site 230
  - post-translational modification (PTM) 1, 7, 8, 13, 79

- acetylation 7
  - ADP ribosylation 7
  - amidation/sulfation 12
  - $\gamma$ -carboxylation 11
  - disulfide bond formation 10–11
  - engineering 12–13
  - extending 12–13
  - glycosylation 8–10
  - $\beta$ -hydroxylation 11
  - importanace 7
  - machinery 8, 80
  - phosphorylation 7
  - profile(s) 7, 12, 14
  - proteolytic cleavage 10–11
  - structure 14
  - post-translational processing 118
  - pregnancy cytotrophoblast cells 126
  - process analytical technology (PAT) 99
  - professional antigen presenting cells 94
  - proinsulin proteolytic processing 10
    - schematic representation 10
  - protein disulfide bond 288
    - formation 279, 288
    - oxidative pathway 279
  - protein disulfide isomerase (PDI) 278, 288
    - DsbG 285
    - proteins folding in ER 289
  - protein folding mechanism 25
    - catalysts classes 277
  - protein glycosylation (pgl) 17, 18, 23, 33, 52, 194
    - biological importance 18
    - characterization 33
    - detection 33
    - glycosylation enzymes 52
    - N/O-linked glycoproteins relationship 23
    - N-glycosylation pathway 169, 181
    - profile 51
  - protein post-translational modification 2–7
  - proteins glycosylation 205
  - protein synthesis 24
  - proteolytic cleavage 10
    - role 10
  - Pseudomonas* strains 201
  - pulsed amperometric detection (PAD) 35
- r**
- rare genetic disorder, *see* Gaucher's disease
  - reactive oxygen species (ROS) 255
  - reagent array analysis method (RAAM) 37
  - recombinant baculoviral vector 165
  - recombinant DNA technology 12
  - recombinant human erythropoietin (rHuEpo) 297
    - amino acid 298, 305
    - carbohydrate glycoforms 302
    - crystal structure of Epo bound 308
    - darbepoetin alfa 303
    - endogenous Epo (eEpo) 298, 299
    - ESAs 310
    - glycopeptide mapping of 299
    - glycosylation analogs 301, 306
    - mammalian cells 297
    - Ser/Thr residues 301
    - serum Epo (sEpo) 299
    - sialic acid-containing carbohydrate 303
    - three-dimensional model of 308
    - urinary Epo (uEpo) 299
  - recombinant human glucocerobrosidase 156
  - recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) 153
  - recombinant monoclonal antibodies 98–100
  - recombinant protein 51, 59, 68, 80, 165, 166
    - expression 149
    - glycosylation 68
    - therapeutic glycoproteins 166
    - TIMP 1 59
  - recombinantly-expressed enzyme 327
    - carbohydrate-remodeled 327
    - cerezyme 327
  - red blood cell (RBC) 297
    - Epo 297
  - remodeling enzymes 330
    - $\alpha$ -mannosidase I 330
  - rheumatoid factor (RF) 90
  - rough endoplasmic reticulum (RER) 22, 23, 24
    - membrane 24, 25
    - secretory pathway 23, 24
- s**
- Saccharomyces cerevisiae* 150, 264
  - Schizosaccharomyces pombe* 152
  - second-generation ERT development 327
    - CHO cell-expressed recombinant human GCCase-cerezyme production 327
    - enzymes biochemical comparison 327–330
    - recombinant technology 327
  - serum acid phosphatase activity 326
  - serum protein mannan binding lectin (MBL) 94
  - Sf9 cells 169, 175, 179, 184
    - baculovirus-infected 169
    - endogenous processing GlcNAcase 184
    - sialic acid-9-phosphate synthase (SAS) 177
    - sialyl-Lewis X glycan structures 54
    - sialyl transferase (ST) enzyme 52, 54, 60, 183
  - signal recognition particle (SRP) 24

- sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 36, 119
  - soluble periplasmic protein 282
    - DsbC 282
  - spinner cell culture system 327
  - steroid hormone production 109
  - Streptococcus pyogenes* 89
  - Streptomyces lividans* 265
  - structural microheterogeneity 114–121
  - sugar processing enzymes 177
  - surface plasmon resonance (SPR) 331
  - systems biology 100
- t**
- tangential flow ultrafiltration (TFF) 267
  - targeting mechanism 172
  - therapeutic antibody 97
    - cetuximab 97
    - glycoform profile 97
  - therapeutic protein(s) 1, 6, 8, 11, 12, 13, 149, 173
    - biopharmaceutical sector 1
    - examples 11
    - glycosylation characteristics 8–9
    - levemir 13
    - post-translational modifications 1, 6
    - production 154
    - remodeling yeast glycosylation 154
  - thioredoxin reductase (trxB) 286, 287
    - gene coding 287
  - Thomsen–Friedenreich (T/TF) antigen 29
  - thrombin-thrombomodulin complex 222
    - activated form of PC (APC) 222
    - zymogen 222
  - thrombolytic therapy 223
  - thrombopoietin 349
  - thyroid-stimulating hormone (TSH) 111
    - glycoforms 129
  - thyrotropin-releasing hormone (TRH) 128
  - TIM barrel catalytic core 321
  - time of flight (TOF) analysis 41
  - tissue plasminogen activator (tPA) 277, 287
  - total correlation spectroscopy (TOCSY) 40
  - trans*-Golgi 58
    - glycosylation process 58
    - network 12, 24
  - transgenic glycosyltransferases 179
    - galactosyltransferase 179
    - N-acetylglucosaminyltransferase II 180
    - sialyltransferase 179
  - transgenic insect cell line 178, 179, 181
    - proof of concept 178
    - transgenic glycosyltransferases 179
    - transgenic sugar processing genes 180
    - transposon-based systems use 181
  - transmembrane protein 91
  - trimming enzymes 22
    - glycosidases 22
  - 2,4,6-trinitrobenzene-1-sulfonate (TNBS) 39
  - Trypanosoma cruzi* 176
- u**
- UDP-N-acetylglucosamine (UDP-GlcNAc) 176, 177
    - epimerase levels 177
  - undecaprenol-pyrophosphate (Und-PP) lipid 199
  - ureidoglycolate lyase (UGL) 256
  - US food and drug administration (FDA) 326
- v**
- vitamin K-dependent proteins 212, 218
    - coumarin-based antagonists 218
    - dependent proteins 212
    - factor IX (FIX) 229
    - factor X (FX) 229
    - hemostasis function 223
    - liver 219
    - polypeptides 217
    - redox cycle 218
- w**
- Walker–Warburg syndrome (WWS) 154
  - weak anion exchange high-performance liquid chromatography (WAX-HPLC) 38
  - western equine encephalitis virus 167
  - Wollinella succinogenes* 194
- x**
- Xenopus laevis* 264
  - Xigiris, *see* activated protein C
- y**
- yeast engineering 149
  - yeast expression systems 334
  - yeast glycosylation 149
    - pathway 155